The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
about
Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophagesHIV type 1 Gag as a target for antiviral therapyNatural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief OverviewComputational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsCellular imaging: a key phenotypic screening strategy for predictive toxicologyA topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu miceExcision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinaseDifferent distribution of HIV-1 subtype and drug resistance were found among treatment naïve individuals in Henan, Guangxi, and Yunnan province of ChinaA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroRecent Insights into the HIV/AIDS Pandemic.Latency reversal and viral clearance to cure HIV-1.An evaluation of the RNase H inhibitory effects of Vietnamese medicinal plant extracts and natural compounds.Controlling the HIV/AIDS epidemic: current status and global challengesTowards an improved anti-HIV activity of NRTI via metal-organic frameworks nanoparticles.From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasmaImmunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirsDisparities in HIV Clinical Outcomes among a Cohort of HIV-Infected Persons Receiving Care-Mississippi.Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus.Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes.Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.Translational research in behavior analysis: historical traditions and imperative for the futureEvaluation of salivary flow rate and gustatory function in HIV-positive patients with or without highly active antiretroviral therapy.New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI).Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system.Treatment of postoperative infectious complications in patients with human immunodeficiency virus infection.Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidineZidovudine and Lamivudine for HIV Infection.Resistance evolution in HIV - modeling when to intervene.Prevention and treatment of surgical site infection in HIV-infected patientsIndividualised motivational counselling to enhance adherence to antiretroviral therapy is not superior to didactic counselling in South African patients: findings of the CAPRISA 058 randomised controlled trialAnalyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histoculturesSequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance.Type and composition of surfactants mediating gene transfection of polyethylenimine-coated liposomes.Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neuronsSynthesis of (carbo)nucleoside analogues by [3+2] annulation of aminocyclopropanes.Clinical management of HIV drug resistance.Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach.A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa
P2860
Q21135536-2072763A-78B1-4A40-ACF1-AD94D3FCCCE6Q24614498-83A48533-7E19-46B1-BD37-28FA1427455DQ26770401-C1FE8F3F-558C-4501-BE1A-FE581D0649BEQ26777448-268EF47D-323C-4819-AAD9-556BA666C37DQ26781577-5E8A4FE2-E4E9-49A6-8717-CE19C814FF50Q28478394-DEAE5BFC-39A2-4B66-A423-3123461CF8CFQ28480614-C3109E82-2EE7-4711-BE17-B48B4916116CQ28534045-A3376697-ADC2-4AC9-A935-40CC4386D5C0Q28728917-75B352BA-755F-46D6-8940-96D9F900A324Q30235024-A01BA56A-9802-4C5F-94AA-48DCD2AC8AE1Q30248766-1D4EA0D8-240C-465F-AC25-F7AA6C56FB98Q30402894-51D0EC4C-4330-4D02-BD61-C4172695D3CDQ30420558-FA444BE3-7528-4E7F-A044-85A822F05760Q30649947-9B258EAB-EA2A-4D32-9ACC-FCBEAA0D4726Q30925594-E4C9C17A-2600-46DA-8920-2C6F068A2AE2Q31004772-6805E284-DAE0-439E-A871-B9AACAA0B8CFQ33604776-CD481190-2183-451D-AB4E-591B023D1413Q33616163-DA9082AA-6E4D-45E2-9AED-AE97FDE7CB8DQ33635155-E0A819BD-E56E-4639-9C5B-DF818D0F2EFDQ33660210-B011A025-5CF8-49EF-888C-D26641AC4E2BQ33784852-CD5B0421-7E97-4C79-A93E-B1788909FCF1Q33819517-F2FDB3BD-97A7-4635-BAA8-3CC83333202DQ33886880-923852B6-5993-49DD-9A67-4086D0545EA1Q33927439-5BD749EF-4508-4624-91D0-67545D918337Q33957533-CBEB9B0F-CE54-45C7-AE88-CB6A6F3A3EAFQ34032359-5C346BCC-6B06-46AC-BF06-3EA15152C1AAQ34060532-C8E6ED97-0C21-43CD-B5F4-CD0518577D07Q34194561-4F79913F-EA89-402F-914F-F19983E68767Q34247013-F4860EE4-356E-4FC6-A653-C918CF3BEFF1Q34268117-781C7D83-7562-4800-AD5A-B15699A55B02Q34288207-A626AC07-30B7-4190-B444-D291A2A4C763Q34728884-2C60D46F-F68A-47E0-BC9E-57C24D9435BDQ35014689-82A8A0B1-53C5-44DE-A27C-B1DFE744B7F6Q35051539-AD902F68-F526-4396-AF40-FE114CC0D930Q35071617-ED37DB2C-8C90-4F2B-A525-C530D26BC37CQ35145361-D12BE315-0D5D-4174-BA06-DB6D2DDE3720Q35194222-11E2489C-9053-44C8-B3F9-A24C7A94CFBAQ35261045-BD989234-3FE0-4462-B1C7-2E04D9DE8E80Q35422530-EBD23EEF-3066-4D31-810A-85E12248CBF7Q35540921-C799E598-8E8C-402D-91C4-EAC7E23E5922
P2860
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@ast
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@en
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@nl
type
label
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@ast
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@en
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@nl
prefLabel
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@ast
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@en
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@nl
P2860
P921
P3181
P1433
P1476
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
@en
P2093
Samuel Broder
P2860
P3181
P356
10.1016/J.ANTIVIRAL.2009.10.002
P407
P577
2010-01-01T00:00:00Z